As GLP-1 receptor agonists move beyond blood sugar and weight loss, a new review shows why clinicians must combine their growing promise with tighter monitoring, safer prescribing and fairer access.
GLP-1 Receptor Agonists: The Good, the Bad and the Ugly – A Complete Guide to NPs. Image credit: zimmytws / Shutterstock
A recent review posted on The Nurse highlights the expanding clinical role of glucagon-like peptide-1 receptor agonists (GLP-1RAs), which have also attracted media attention for their rapid weight loss results.
It is widely used for type 2 diabetes (T2D) and obesity, these agents offer benefits beyond glycemic control, including cardiovascular protection, with emerging evidence suggesting broader metabolic and potential neurocognitive effects.
As evidence continues to grow, the review highlights that nurse practitioners (NPs) must balance enthusiasm with vigilance. They should recognize patient-related side effects and risks while adjusting therapy as weight and metabolic markers such as glycated hemoglobin (HbA1c) and lipid profiles evolve.
GLP-1RAs are now a mainstay in frontline care T2Dobesity and related diseases. These agents improve glycemic control, lower blood pressure, support weight loss, and offer well-documented cardioprotective benefits.
While public interest has boosted their profile, clinical trial evidence supporting glycemic, weight, blood pressure and cardiovascular benefits has aided adoption.
As their use expands, NPs they play a central role in guiding appropriate prescribing, educating patients and monitoring outcomes. This growing role makes it essential for NPs to understand its full scope GLP-1RA indications, benefits and risks to ensure safe, effective and equitable care.
Clinical Benefits and Mechanisms of GLP-1RAs
In this review, researchers examine the indications, benefits, risks, and prescribing considerations GLP-1RAswith the aim of equipping NPs with practical, evidence-based guidance to optimize their use in clinical practice. Criticism also frames GLP-1RA use in the context of rising obesity rates, significant health care costs, and the high overlap between obesity and diagnosed diabetes.
GLP-1RAs mimics endogenous GLP-1, an incretin hormone released after food intake. They enhance glucose-dependent insulin secretion, suppress glucagon release and slow gastric emptying, while supporting the maintenance of pancreatic beta-cell function. Since these agents are resistant to rapid enzymatic degradation, they retain prolonged metabolic activity.
Several GLP-1RAsincluding exenatide, dulaglutide, semaglutide, and liraglutide, are approved for T2Dalongside tirzepatide, which also acts on the glucose-dependent insulinotropic polypeptide (GIP) receptors. While the formulations differ in dosing frequency, onset, and tolerability, they generally exhibit comparable safety and efficacy.
Options include once-weekly injectables, daily agents, combination insulin therapies, and newer oral formulations that some patients may prefer, although tolerability and discontinuation remain issues.
In all trials, 30% to 80% of patients achieve hemoglobin A1c goals of less than 7%, with semaglutide often producing the greatest reductions. These agents also promote weight loss of 5.0% to 20% over several months and improve blood pressure and lipid profiles.
Important instructions are recommended GLP-1RAs as first-line therapy in patients with T2D who have or are at high risk for atherosclerotic cardiovascular disease, chronic kidney disease (CKD), or obesity.
Beyond glycemic control, GLP-1RAs they offer cardioprotective and neuroprotective effects, reduce major cardiovascular events and have a low risk of hypoglycemia. Some cardiovascular benefits may be partially mediated by improved glycemic control and weight loss.
Emerging data also show benefits in conditions such as obstructive sleep apnea (OSA) and chronic kidney disease, including tirzepatide for moderate to severe OSA in adults with obesity and semaglutide to reduce renal and cardiovascular risk in adults with CKD and T2D.
For NPsthese general effects highlight the importance of aligning drug selection with individual patient profiles while monitoring metabolic response and overall health outcomes.
GLP-1RA Prescribing Risks and Issues
GLP-1RAs they are generally well tolerated, but careful prescribing and patient counseling remain essential. Gastrointestinal effects are the most common. Patients often report nausea, vomiting, bloating, or bowel changes early in treatment. These symptoms often improve over time with continued use in most patients and NPs can reduce discontinuation by starting at a low dose and titrating gradually. Strategies such as hydration, smaller meals, adjusting fiber intake based on symptoms, and avoiding high-fat foods can relieve symptoms.
Dosage and administration require attention to detail. Oral semaglutide should be taken on an empty stomach at least 30 minutes before food or other medications, while short-acting agents such as exenatide should be timed with meals.
Injectable formulations benefit from site rotation to minimize local reactions. As patients lose weight and metabolic control improves, clinicians should reassess concomitant therapies to reduce the risk of hypoglycemia and polypharmacy, particularly when insulin or sulfonylureas are used.
Patients of childbearing age should also be counseled about contraception and planning pregnancy, as the review notes limited pregnancy data and recommends stopping GLP-1RAs at least two months before the planned conception. Delayed gastric emptying, especially with tirzepatide, may also affect the absorption of oral contraceptives.
Although rare, serious risks require vigilance. These include pancreatitis, gastroparesis, gallbladder and biliary disease and, in selected cases, acute kidney injury associated with dehydration.
Clinicians should exercise caution in patients with a history of pancreatitis or gastroparesis, inflammatory bowel disease, other bowel motility disorders, medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 and discontinue therapy when clinically indicated, such as prior to anesthesia.
The review also notes a temporary worsening of retinopathy associated with diabetes during rapid glycemic improvement, an increased risk of aspiration from delayed gastric emptying, and the need to protect against nutritional deficiencies and loss of muscle or bone mass during rapid weight loss.
Access, Equity and Guidance of Nurse Practitioners
Access and equity also shape actual use. High costs, variable insurance coverage, and risks associated with unapproved compounded products can limit safe access. These risks include dosing errors, sterility concerns, counterfeit products, altered bioavailability, and reduced clinician oversight in some settings.
NPs play a key role in addressing these barriers by advocating for patients and promoting informed, stigma-free discussions that support safe and fair use.
Based on the findings, GLP-1RAs are evolving into multisystem therapies with expanding roles beyond diabetes, including cardiovascular, renal, and hepatic benefits, as well as potential neurocognitive benefits.
As evidence mounts, NPs should align use with individual risk profiles, comorbidities, and treatment goals. They should set realistic expectations, monitor key metabolic markers, and reinforce lifestyle measures through multidisciplinary support.
Clear documentation and payer familiarity can improve access and follow-up, although cost and coverage remain significant barriers. Advocacy, careful patient selection, and evidence-based practice will be necessary to ensure that these therapies are used safely, effectively, and equitably in routine patient care settings.
